Piperidin-4-ol → HCID 67214953, compound
Reaction equation
Cl[C:2]1[CH:7]=[CH:6][C:5]([C:8]2[O:9][C:10]([C:13]3[C:14]([C:19]4[CH:24]=[CH:23][CH:22]=[CH:21][CH:20]=4)=[N:15][O:16][C:17]=3[CH3:18])=[N:11][N:12]=2)=[CH:4][N:3]=1.[OH:25][CH:26]1[CH2:31][CH2:30][NH:29][CH2:28][CH2:27]1>>[CH3:18][C:17]1[O:16][N:15]=[C:14]([C:19]2[CH:24]=[CH:23][CH:22]=[CH:21][CH:20]=2)[C:13]=1[C:10]1[O:9][C:8]([C:5]2[CH:6]=[CH:7][C:2]([N:29]3[CH2:30][CH2:31][CH:26]([OH:25])[CH2:27][CH2:28]3)=[N:3][CH:4]=2)=[N:12][N:11]=1Participants
3
Procedure
As described for example 136b, 2-chloro-5-[5-(5-methyl-3-phenyl-isoxazol-4-yl)-[1,3,4]oxadiazol-2-yl]-pyridine (200 mg, 0.59 mmol) was converted using 4-hydroxypiperidine instead of morpholine to the title compound (17 mg, 7%) which was obtained as a light yellow solid. MS: m/e=404.5 [M+H]+.
Sources & evidence
- ORD record
- ord-db4b7e427a804d2c9cf436f0a00bd164
- Source dataset
- uspto-grants-2009_06
- Patent number
- US07541372B2
Reaction notes
Loading…